BR112020021812A2 - forma de dosagem, método para tratar uma doença, distúrbio, síndrome e/ou afecção em um paciente com necessidade do mesmo, e método para produzir uma forma de dosagem - Google Patents
forma de dosagem, método para tratar uma doença, distúrbio, síndrome e/ou afecção em um paciente com necessidade do mesmo, e método para produzir uma forma de dosagem Download PDFInfo
- Publication number
- BR112020021812A2 BR112020021812A2 BR112020021812-0A BR112020021812A BR112020021812A2 BR 112020021812 A2 BR112020021812 A2 BR 112020021812A2 BR 112020021812 A BR112020021812 A BR 112020021812A BR 112020021812 A2 BR112020021812 A2 BR 112020021812A2
- Authority
- BR
- Brazil
- Prior art keywords
- dosage form
- magnesium
- threonate
- day
- disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862662756P | 2018-04-25 | 2018-04-25 | |
| US62/662,756 | 2018-04-25 | ||
| PCT/US2019/028903 WO2019209943A1 (en) | 2018-04-25 | 2019-04-24 | Magnesium threonate compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020021812A2 true BR112020021812A2 (pt) | 2021-02-23 |
Family
ID=68291941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020021812-0A BR112020021812A2 (pt) | 2018-04-25 | 2019-04-24 | forma de dosagem, método para tratar uma doença, distúrbio, síndrome e/ou afecção em um paciente com necessidade do mesmo, e método para produzir uma forma de dosagem |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11717501B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3784227A4 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2021522344A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20210005662A (cg-RX-API-DMAC10.html) |
| CN (3) | CN120168449A (cg-RX-API-DMAC10.html) |
| AU (2) | AU2019261406A1 (cg-RX-API-DMAC10.html) |
| BR (1) | BR112020021812A2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3098360A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2019209943A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3784227A4 (en) | 2018-04-25 | 2022-03-02 | Neurocentria, Inc. | MAGNESIUM THREONATE COMPOSITIONS AND THEIR USES |
| WO2021245697A1 (en) | 2020-06-01 | 2021-12-09 | Celagenex Research (India) Pvt. Ltd. | Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling |
| KR20230058095A (ko) * | 2020-08-28 | 2023-05-02 | 디에프아이 유에스에이, 엘엘씨. | L-크실론산으로부터 l-트레온산 염을 생산하는 방법 |
| CN115047058A (zh) * | 2021-03-09 | 2022-09-13 | 江苏开元药业有限公司 | 一种测定铝碳酸镁咀嚼片溶出曲线的方法 |
| CN114304610A (zh) * | 2021-12-24 | 2022-04-12 | 苏州麦轮生物科技有限公司 | 一种含有苏糖酸镁的营养补充剂及其应用 |
| WO2024232931A1 (en) * | 2023-05-11 | 2024-11-14 | Yon Doo Ough | Apparatus and method for contact free delivery and administration of magnesium as a drug |
| CN119504413A (zh) * | 2025-01-20 | 2025-02-25 | 浙江天启生化股份有限公司 | 一种l-苏糖酸镁合成方法及应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6010718A (en) * | 1997-04-11 | 2000-01-04 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
| GB0009522D0 (en) * | 2000-04-19 | 2000-06-07 | Smithkline Beecham Plc | Composition |
| DK1524981T3 (da) * | 2002-07-29 | 2009-06-22 | Glaxo Group Ltd | Sammensætninger med vedvarende frigivelse indeholdende lamotrigin |
| AU2008227465B2 (en) * | 2007-03-22 | 2014-02-06 | Magceutics, Inc. | Magnesium compositions and uses thereof |
| US8142803B2 (en) * | 2007-03-22 | 2012-03-27 | Magceutics, Inc. | Magnesium compositions and uses thereof for neurological disorders |
| WO2011003045A1 (en) * | 2009-07-01 | 2011-01-06 | Magceutics, Inc. | Slow release magnesium composition and uses thereof |
| US9943489B2 (en) * | 2010-02-03 | 2018-04-17 | Pharmatwob Ltd. | Extended release formulations of rasagiline and uses thereof |
| CN108289875A (zh) | 2015-09-11 | 2018-07-17 | 纽罗森特里亚股份有限公司 | 苏糖酸盐化合物及其使用方法 |
| CN105326855A (zh) | 2015-10-27 | 2016-02-17 | 南京大学 | 易吸收复合夹层式螯合镁钙片 |
| CN105326955B (zh) * | 2015-11-02 | 2019-04-12 | 北京市眼科研究所 | 一种治疗睑缘炎的组合物及其制备方法 |
| US10617713B2 (en) | 2016-03-08 | 2020-04-14 | Neurocentria, Inc. | Methods of modifying neuronal function by changing intracellular magnesium levels |
| CN107625776A (zh) | 2016-07-19 | 2018-01-26 | 无锡脑镁素生物医药科技有限公司 | 用于改善睡眠的镁组合物及其用途 |
| CN106360734A (zh) | 2016-09-28 | 2017-02-01 | 张家港威胜生物医药有限公司 | 一种同时具有减肥和美容作用的组合物及其制备方法与用途 |
| WO2018200885A1 (en) | 2017-04-26 | 2018-11-01 | Neurocentria, Inc. | Magnesium compositions and methods of use |
| EP3784227A4 (en) | 2018-04-25 | 2022-03-02 | Neurocentria, Inc. | MAGNESIUM THREONATE COMPOSITIONS AND THEIR USES |
-
2019
- 2019-04-24 EP EP19792918.5A patent/EP3784227A4/en active Pending
- 2019-04-24 CN CN202510100404.6A patent/CN120168449A/zh active Pending
- 2019-04-24 US US16/393,298 patent/US11717501B2/en active Active
- 2019-04-24 WO PCT/US2019/028903 patent/WO2019209943A1/en not_active Ceased
- 2019-04-24 CN CN202510100476.0A patent/CN120241690A/zh active Pending
- 2019-04-24 JP JP2021509954A patent/JP2021522344A/ja active Pending
- 2019-04-24 BR BR112020021812-0A patent/BR112020021812A2/pt unknown
- 2019-04-24 KR KR1020207033637A patent/KR20210005662A/ko active Pending
- 2019-04-24 CA CA3098360A patent/CA3098360A1/en active Pending
- 2019-04-24 CN CN201980042120.9A patent/CN112384210A/zh active Pending
- 2019-04-24 AU AU2019261406A patent/AU2019261406A1/en not_active Abandoned
-
2023
- 2023-06-15 US US18/210,515 patent/US20240156761A1/en active Pending
-
2024
- 2024-10-11 JP JP2024178890A patent/JP2025011238A/ja active Pending
-
2025
- 2025-02-27 AU AU2025201393A patent/AU2025201393A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019261406A1 (en) | 2020-12-17 |
| US11717501B2 (en) | 2023-08-08 |
| US20240156761A1 (en) | 2024-05-16 |
| US20190328689A1 (en) | 2019-10-31 |
| EP3784227A1 (en) | 2021-03-03 |
| AU2025201393A1 (en) | 2025-03-20 |
| CN112384210A (zh) | 2021-02-19 |
| CN120168449A (zh) | 2025-06-20 |
| JP2021522344A (ja) | 2021-08-30 |
| CN120241690A (zh) | 2025-07-04 |
| EP3784227A4 (en) | 2022-03-02 |
| WO2019209943A1 (en) | 2019-10-31 |
| KR20210005662A (ko) | 2021-01-14 |
| JP2025011238A (ja) | 2025-01-23 |
| CA3098360A1 (en) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240156761A1 (en) | Magnesium Threonate Compositions and Uses Thereof | |
| JP2022522270A (ja) | 食事摂取状態における改善された薬物動態を有するガンマ-ヒドロキシ酪酸塩組成物 | |
| ES2606463T3 (es) | Combinación de formas de dosificación de levodopa/carbidopa de liberación inmediata y liberación controlada | |
| NO336938B1 (no) | Farmasøytisk sammensetning av vedvarende frigjøringsformulering av amfetaminer eller amfetaminsalter | |
| CN109475510B (zh) | 普瑞巴林的延长释放剂型 | |
| CN109223725A (zh) | 用于以低的日剂量施用的含富马酸二甲酯的药物组合物 | |
| ES2408343A2 (es) | Composiciones farmacéuticas que comprenden hidromorfona y naloxona | |
| MXPA06002023A (es) | Nueva formulacion de ropinirol. | |
| JP2022518703A (ja) | ホスホジエステラーゼ阻害剤を含有する放出調節錠剤製剤 | |
| JP2021506944A (ja) | 持続放出ミドドリン塩酸塩組成物及び使用方法 | |
| JPS62501845A (ja) | 制御放出塩化カリウム | |
| JP2022522005A (ja) | Tbn、又はその塩もしくは水和物を含む薬物組成物及びその製造方法 | |
| WO2017101858A1 (zh) | 环苄普林之延释剂型 | |
| WO2017084486A1 (zh) | 简易制备结肠炎和克罗恩病用高载药量缓释制剂的方法 | |
| TW200800155A (en) | Gastric retentive gabapentin dosage forms and methods for using same | |
| CN101756981B (zh) | 一种布洛氯雷伪麻缓释制剂及其制备方法 | |
| AU780505B2 (en) | Sustained-release formulations for treating CNS-mediated disorders | |
| JP2016539171A (ja) | アセブロフィリン及び疎水性徐放性基剤を含む徐放性薬学組成物 | |
| ES2317450T3 (es) | Formulacion de liberacion controlada de acido valproico y sus derivados. | |
| CN110384669A (zh) | 一种司美替尼及其衍生物的新剂型及制备方法 | |
| BR102023025187A2 (pt) | Forma farmacêutica oral para liberação bifásica, composta por um sistema multiparticulado, processo para preparação da mesma e uso terapêutico da forma oral | |
| WO2025111679A1 (pt) | Forma farmacêutica oral para liberação bifásica, composta por um sistema multiparticulado, processo para preparação da mesma e uso terapêutico da forma oral | |
| WO2022133555A1 (pt) | Composição farmacêutica sólida contendo vitamina d e sal de cálcio, método para tratar ou prevenir condições relacionadas a baixa ingestão e/ou maior necessidade de cálcio, uso da composição farmacêutica sólida e produto farmacêutico ou suplementar | |
| CN117653609A (zh) | 一种枸橼酸托法替布缓释制剂 | |
| CN121370795A (zh) | 一种维立西呱缓释片及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: NEUROCENTRIA, INC. (US) |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |